Found 6 matching trials
Phase I Trial of BI 836845 for Various Solid Cancer PHASE1 This study is a phase I, open-label, dose escalation trial to determine the...
Show More Location
China Medical University Hospital
Learn More & Join Trial
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer PHASE1 Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended...
Show More Location
Medical University of Graz State Hospital - University Hospital Graz
Learn More & Join Trial
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types PHASE1 This study is a phase I, open-label, dose escalation trial to determine the...
Show More Location
St James's University Hospital
Learn More & Join Trial
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) PHASE1 Part A: To determine the maximum tolerated dose (MTD) and/or recommended ph...
Show More Location
National Hospital Organization Kyushu Cancer Center
Learn More & Join Trial
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours PHASE1 This open-label dose escalation phase I trial, 1280.15, is with the first a...
Show More Location
National Cancer Center Hospital East
Learn More & Join Trial
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) PHASE1 The overall aim of the trial is to investigate the safety and anti-tumour a...
Show More Location
Karmanos Cancer Institute
Learn More & Join Trial